Equillium, Inc.
NASDAQ:EQ · NASDAQ Global Market
+$0.00 today
Vol 0.24M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-78.3%
avg -50.8%
ROIC
-83.3%
avg -53.6%
ROA
-70.2%
avg -42.9%
Analysis
ROA is currently the strongest return metric at -70.2% versus its period average of -42.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bruce D. Steel | Co-Founder, Chief Executive Officer & Director | $1.23M | — | 60 | $1.75M | 4.93% |
Stephen Connelly | Chief Scientific Officer & President | $926,562.00 | — | 45 | $762,025.00 | 2.15% |
Christine Zedelmayer | Senior Vice President & Chief Operating Officer | $810,292.00 | — | 56 | $62,586.00 | 0.18% |
Lisette Acevedo | Vice President of Clinical Development | — | — | — | — | — |
Snehal Naik | Chief Development Officer | — | — | — | — | — |
Penny Tom | Senior Vice President of Finance & Principal Accounting Officer | — | — | — | $65,000.00 | 0.18% |
Michael Moore | Vice President of Investor Relations & Corporate Communications | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
20
$2.76M
Net Sentiment
$2.76M
Net selling
Most Active
Zedelmayer Christine
16 transactions
1–10 of 20
Analysis
Insiders reported 0 buys worth $0.00 and 20 sells worth $2.76M over the last 12 months. That adds up to net selling of $2.76M. Zedelmayer Christine was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$194.78M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
Cue Biopharma, Inc.
NASDAQ:CUE
$64.46M
Coeptis Therapeutics, Inc.
COEP
$57.63M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
Telomir Pharmaceuticals, Inc. Common Stock
TELO
$43.32M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
Who manages EQ?
Equillium, Inc. (EQ) lists 7 active executives. The top listed executive is Lisette Acevedo, Vice President of Clinical Development.
Are EQ insiders buying or selling?
Recent insider activity shows net buying of $2.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.